These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26999331)

  • 1. Inhibition of mTOR enhances radiosensitivity of lung cancer cells and protects normal lung cells against radiation.
    Zheng H; Wang M; Wu J; Wang ZM; Nan HJ; Sun H
    Biochem Cell Biol; 2016 Jun; 94(3):213-20. PubMed ID: 26999331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
    Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
    Mauceri HJ; Sutton HG; Darga TE; Kocherginsky M; Kochanski J; Weichselbaum RR; Vokes EE
    Oncol Rep; 2012 May; 27(5):1625-9. PubMed ID: 22294050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy.
    Anandharaj A; Cinghu S; Park WY
    Acta Biochim Biophys Sin (Shanghai); 2011 Apr; 43(4):292-300. PubMed ID: 21367753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells.
    Cheng KY; Hao M
    Med Sci Monit; 2017 Apr; 23():2017-2028. PubMed ID: 28446743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-dependent protein kinase catalytic subunit inhibitor reverses acquired radioresistance in lung adenocarcinoma by suppressing DNA repair.
    Li Y; Li H; Peng W; He XY; Huang M; Qiu D; Xue YB; Lu L
    Mol Med Rep; 2015 Jul; 12(1):1328-34. PubMed ID: 25815686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY; Lv YF; Lu L; Cai L
    Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH
    Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.
    Dumont FJ; Bischoff P
    Curr Cancer Drug Targets; 2012 Oct; 12(8):899-924. PubMed ID: 22831276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
    Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
    Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.
    Schiewer MJ; Den R; Hoang DT; Augello MA; Lawrence YR; Dicker AP; Knudsen KE
    Endocr Relat Cancer; 2012 Feb; 19(1):1-12. PubMed ID: 21903859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer.
    Kim KW; Hwang M; Moretti L; Jaboin JJ; Cha YI; Lu B
    Autophagy; 2008 Jul; 4(5):659-68. PubMed ID: 18424912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
    Xu X; Jiang J; Yao L; Ji B
    Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation.
    Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
    Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
    Djuzenova CS; Fiedler V; Memmel S; Katzer A; Sisario D; Brosch PK; Göhrung A; Frister S; Zimmermann H; Flentje M; Sukhorukov VL
    BMC Cancer; 2019 Apr; 19(1):299. PubMed ID: 30943918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down regulation of mammalian target of rapamycin decreases HIF-1α and survivin expression in anoxic lung adenocarcinoma A549 cell to elemene and/or irradiation.
    Zou K; Tong E; Xu Y; Deng X; Zou L
    Tumour Biol; 2014 Oct; 35(10):9735-41. PubMed ID: 24972968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.
    Cao C; Subhawong T; Albert JM; Kim KW; Geng L; Sekhar KR; Gi YJ; Lu B
    Cancer Res; 2006 Oct; 66(20):10040-7. PubMed ID: 17047067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.